These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22592607)

  • 1. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
    Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
    Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous T cells on the attack against AML.
    Berneman ZN
    Blood; 2012 Aug; 120(6):1151-2. PubMed ID: 22879624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
    Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
    Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
    Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).
    Greiner J; Schneider V; Schmitt M; Götz M; Döhner K; Wiesneth M; Döhner H; Hofmann S
    Blood; 2013 Aug; 122(6):1087-8. PubMed ID: 23929838
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.
    Peng M; Ren J; Jing Y; Jiang X; Xiao Q; Huang J; Tao Y; Lei L; Wang X; Yang Z; Yang Z; Zhan Q; Lin C; Jin G; Zhang X; Zhang L
    J Extracell Vesicles; 2021 Nov; 10(13):e12168. PubMed ID: 34807526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
    Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.
    Kuželová K; Brodská B; Fuchs O; Dobrovolná M; Soukup P; Cetkovský P
    PLoS One; 2015; 10(5):e0127637. PubMed ID: 25992555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1
    De Cicco M; Lagreca I; Basso S; Barozzi P; Muscianisi S; Bianco A; Riva G; Di Vincenzo S; Pulvirenti C; Sapuppo D; Siciliano M; Rosti V; Candoni A; Zecca M; Forghieri F; Luppi M; Comoli P
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
    Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
    Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Simonetti G; Mengucci C; Padella A; Fonzi E; Picone G; Delpino C; Nanni J; De Tommaso R; Franchini E; Papayannidis C; Marconi G; Pazzaglia M; Perricone M; Scarpi E; Fontana MC; Bruno S; Tebaldi M; Ferrari A; Bochicchio MT; Ghelli Luserna Di Rorà A; Ghetti M; Napolitano R; Astolfi A; Baldazzi C; Guadagnuolo V; Ottaviani E; Iacobucci I; Cavo M; Castellani G; Haferlach T; Remondini D; Capozzi F; Martinelli G
    Leukemia; 2021 Oct; 35(10):2813-2826. PubMed ID: 34193978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
    Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
    Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.